Portal de Periódicos da CAPES

Durability of the Tumor-Free Response for Intravesical Bacillus Calmette-Guerin Therapy

1994; Lippincott Williams & Wilkins; Volume: 152; Issue: 2 Part 1 Linguagem: Inglês

10.1016/s0022-5347(17)32741-6

1527-3792

Robert Nadler, William J. Catàlona, M’Liss A. Hudson, Timothy L. Ratliff,

Polyomavirus and related diseases

No AccessJournal of Urology1 Aug 1994Durability of the Tumor-Free Response for Intravesical Bacillus Calmette-Guerin Therapy Robert B. Nadler, William J. Catalona, M'liss A. Hudson, and Timothy L. Ratliff Robert B. NadlerRobert B. Nadler , William J. CatalonaWilliam J. Catalona , M'liss A. HudsonM'liss A. Hudson , and Timothy L. RatliffTimothy L. Ratliff View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)32741-6AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The long-term efficacy of bacillus Calmette-Guerin (BCG) has not been established. We describe the tumor-free status of patients 11 years after BCG treatment. Long-term followup for the patient population (mean 74.3 ± 3.5 months, range 6 to 129) yielded a 28% (29 of 104 patients) tumor-free status for a single 6-week course of BCG. Of 66 patients who received a second 6-week course of BCG for recurrent tumors after failing the initial 6-week course 27 (41%) have remained tumor-free. Overall, 56 of 104 patients (54%) remain tumor-free after 1 or 2 courses of BCG. Analysis of recurrences with respect to 3 intervals (2 or less, 2 to 5 and more than 5 years) revealed recurrence rates of 61% (63 of 104 patients), 23% (7 of 30) and 22% (5 of 23), respectively, after 1, 6-week course of BCG. Similarly, recurrence rates for the same periods for patients receiving a second 6-week course of BCG were 42% (28 of 66), 21% (6 of 28) and 23% (5 of 22), respectively. Patients receiving either 1 or 2, 6-week BCG courses who were tumor-free at 2 years experienced essentially identical recurrence rates during the 2 to 11-year followup (36% and 33%, respectively). Overall, 23 of 66 patients (35%) who were tumor-free at 2 years had recurrent tumors during the 2 to 11-year followup. We conclude that while BCG is effective therapy for superficial bladder tumors, a continuous potential for tumor recurrence exists for responding patients necessitating life-long followup. © 1994 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byRosevear H, Lightfoot A, Birusingh K, Maymí J, Nepple K and O'Donnell M (2018) Factors Affecting Response to Bacillus Calmette-Guérin Plus Interferon for Urothelial Carcinoma in SituJournal of Urology, VOL. 186, NO. 3, (817-823), Online publication date: 1-Sep-2011.Nativ O, Witjes J, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R and Leibovitch I (2018) Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-GuerinJournal of Urology, VOL. 182, NO. 4, (1313-1317), Online publication date: 1-Oct-2009.SOLSONA E, IBORRA I, RICÓS J, MONRÓS J, RUBIO J and ALMENAR S (2018) Clinical Panurothelial Disease in Patients with Superficial Bladder Tumors: Therapeutic ImplicationsJournal of Urology, VOL. 167, NO. 5, (2007-2011), Online publication date: 1-May-2002.O'DONNELL M, KROHN J and DeWOLF W (2018) SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILEDJournal of Urology, VOL. 166, NO. 4, (1300-1305), Online publication date: 1-Oct-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.LOSA A, HURLE R and LEMBO A (2018) LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTSJournal of Urology, VOL. 163, NO. 1, (68-72), Online publication date: 1-Jan-2000.MONTIE J (2018) AGAINST BLADDER SPARING: SURGERYJournal of Urology, VOL. 162, NO. 2, (452-455), Online publication date: 1-Aug-1999.Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H and Marberger M (2018) DOES TOPICAL INSTILLATION THERAPY INFLUENCE CHROMOSOMAL ABERRATIONS IN SUPERFICIAL BLADDER CANCER?Journal of Urology, VOL. 159, NO. 1, (265-269), Online publication date: 1-Jan-1998.Ovesen H, Horn T and Steven K (2018) Long-Term Efficacy of Intravesical Bacillus Calmette-Guerin for Carcinoma in Situ: Relationship of Progression to Histological Response and p53 Nuclear AccumulationJournal of Urology, VOL. 157, NO. 5, (1655-1659), Online publication date: 1-May-1997.Zlotta A, Drowart A, Van Vooren J, de Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman C and Huygen K (2018) Evolution and Clinical Significance of the T Cell Proliferative and Cytokine Response Directed Against the Fibronectin Binding Antigen 85 Complex of Bacillus Calmette-Guerin During Intravesical Treatment of Superficial Bladder CancerJournal of Urology, VOL. 157, NO. 2, (492-498), Online publication date: 1-Feb-1997.Lundholm C, Norlen B, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, Olsson J, Tveter K, Westberg R and Malmstrom P (2018) A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, VOL. 156, NO. 2, (372-376), Online publication date: 1-Aug-1996.Zhang G, Uke E, Sharer W, Borkon W and Bernstein S (2018) Reassessment of Conservative Management for Stage T1N0M0 Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 155, NO. 6, (1907-1909), Online publication date: 1-Jun-1996.Hudson M and Herr H (2018) Carcinoma in Situ of the BladderJournal of Urology, VOL. 153, NO. 3, (564-572), Online publication date: 1-Mar-1995. Volume 152Issue 2 Part 1August 1994Page: 367-373 Advertisement Copyright & Permissions© 1994 by The American Urological Association Education and Research, Inc.KeywordsBCG vaccinebladder neoplasmsMetricsAuthor Information Robert B. Nadler More articles by this author William J. Catalona More articles by this author M'liss A. Hudson More articles by this author Timothy L. Ratliff More articles by this author Expand All Advertisement PDF downloadLoading ...